Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3131 publications

Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials.

Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials.

Journal: Melanoma management
Published: December 12, 2025

TRMU Confers Resistance of Melanoma Cells to Vemurafenib through Modulating Mitochondrial Activities.

TRMU Confers Resistance of Melanoma Cells to Vemurafenib through Modulating Mitochondrial Activities.

Journal: Journal of proteome research
Published: November 10, 2025

Maintenance Low-Dose BRAF Inhibition and Rituximab in Relapsed Hairy Cell Leukemia: A Therapeutic Alternative.

Maintenance Low-Dose BRAF Inhibition and Rituximab in Relapsed Hairy Cell Leukemia: A Therapeutic Alternative.

Journal: Cureus
Published: October 29, 2025

Combining Bioactive Cell-Penetrating Peptides and Vemurafenib to Produce Peptide-Drug Conjugates with Activity Against Drug-Resistant Melanoma Cells.

Combining Bioactive Cell-Penetrating Peptides and Vemurafenib to Produce Peptide-Drug Conjugates with Activity Against Drug-Resistant Melanoma Cells.

Journal: Journal of medicinal chemistry
Published: October 27, 2025

Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma.

Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma.

Journal: Journal of medicinal chemistry
Published: October 17, 2025

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib.

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib.

Journal: Journal of clinical medicine
Published: October 08, 2025

Targeting centromere protein M represses cell growth and mobility via inactivating AKT pathway but less affects BRAF inhibitor sensitivity in cutaneous melanoma.

Targeting centromere protein M represses cell growth and mobility via inactivating AKT pathway but less affects BRAF inhibitor sensitivity in cutaneous melanoma.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 29, 2025

Cellular and Molecular Effects of Targeting the CBP/β-Catenin Interaction with PRI-724 in Melanoma Cells, Drug-Naïve and Resistant to Inhibitors of BRAFV600 and MEK1/2.

Cellular and Molecular Effects of Targeting the CBP/β-Catenin Interaction with PRI-724 in Melanoma Cells, Drug-Naïve and Resistant to Inhibitors of BRAFV600 and MEK1/2.

Journal: Cells
Published: September 17, 2025

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.

Journal: Archivos argentinos de pediatria
Published: September 16, 2025

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Journal: HemaSphere
Published: September 08, 2025

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study.

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study.

Journal: RSC medicinal chemistry
Published: September 06, 2025

Harnessing retinoic acid metabolism-related genes to identify lung adenocarcinoma subtype and establish a risk model for predicting prognosis and drug therapy response.

Harnessing retinoic acid metabolism-related genes to identify lung adenocarcinoma subtype and establish a risk model for predicting prognosis and drug therapy response.

Journal: Computational biology and chemistry
Published: September 02, 2025
Showing 1-12 of 3,131

Last Updated: 01/07/2026